Literature DB >> 10594400

Omeprazole, clarithromycin and furazolidone for the eradication of Helicobacter pylori in patients with duodenal ulcer.

R Dani1, D M Queiroz, M G Dias, J M Franco, L C Magalhães, G S Mendes, L S Moreira, L P De Castro, N H Toppa, G A Rocha, M M Cabral, P G Salles.   

Abstract

AIM: To evaluate the efficacy of omeprazole plus clarithromycin and furazolidone in Helicobacter pylori eradication and duodenal ulcer healing in Brazilian patients.
METHODS: Forty H. pylori-positive patients with duodenal ulcer were randomized to receive 20 mg omeprazole o.m. or b.d. for 1 month plus 500 mg clarithromycin (b.d. ) and 200 mg furazolidone (b.d.) for 1 week.
RESULTS: Three months after the end of the treatment the eradication rates were 90% by intention-to-treat analysis, and 97% by per protocol analysis. Mild side-effects were observed in 25 patients, none of whom abandoned the protocol. No difference was observed between the 20 mg and 40 mg omeprazole daily doses. Cure or significant improvement of the symptoms and of the histological alterations were observed after H. pylori eradication.
CONCLUSION: Our results demonstrate that clarithromycin and furazolidone in combination with omeprazole are a good alternative for H. pylori eradication in Brazilian patients with duodenal ulcer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10594400     DOI: 10.1046/j.1365-2036.1999.00653.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  7 in total

1.  Evaluation of nitrofurantoin combination therapy of metronidazole-sensitive and -resistant Helicobacter pylori infections in mice.

Authors:  P J Jenks; R L Ferrero; J Tankovic; J M Thiberge; A Labigne
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

2.  Effect of acid secretion blockade by omeprazole on the relative bioavailability of orally administered furazolidone in healthy volunteers.

Authors:  S A Calafatti; R A Ortiz; M Deguer; M Martinez; J Pedrazzoli
Journal:  Br J Clin Pharmacol       Date:  2001-08       Impact factor: 4.335

3.  Furazolidone-based triple therapy for H pylori gastritis in children.

Authors:  Elisabete Kawakami; Rodrigo Strehl Machado; Silvio Kazuo Ogata; Marini Langner; Erika Fukushima; Anna Paula Carelli; Vania Cláudia Guimarães Bonucci; Francy Reis Silva Patricio
Journal:  World J Gastroenterol       Date:  2006-09-14       Impact factor: 5.742

4.  Long-term effect of Helicobacter pylori eradication on plasma homocysteine in elderly patients with cobalamin deficiency.

Authors:  Marília Campos Abreu Marino; Celso Affonso de Oliveira; Andreia Maria Camargos Rocha; Gifone Aguiar Rocha; Nelma Cristina Diogo Clementino; Leonardo França Antunes; Ricardo Araújo Oliveira; Almir Sousa Martins; Helen Lima Del Puerto; Vânia D'Almeida; Luciano Galdieri; Enio Roberto Pietra Pedroso; Mônica Maria Demas Alvares Cabral; Ana Margarida Miguel Ferreira Nogueira; Dulciene Maria Magalhães Queiroz
Journal:  Gut       Date:  2006-09-27       Impact factor: 23.059

Review 5.  Furazolidone-based therapies for Helicobacter pylori infection: a pooled-data analysis.

Authors:  Angelo Zullo; Enzo Ierardi; Cesare Hassan; Vincenzo De Francesco
Journal:  Saudi J Gastroenterol       Date:  2012 Jan-Feb       Impact factor: 2.485

6.  A Comparison between Moderate- and High-dose Furazolidone in Triple Regimens for Helicobacterpylori Eradication in Iran.

Authors:  Vahid Hosseini; Marjan Mokhtare; Mohsen Gholami; Tarang Taghvaei; Iradj Maleki; Mohammad Valizadeh; Zohreh Bari; Hafez Fakheri
Journal:  Middle East J Dig Dis       Date:  2014-10

7.  Short-duration furazolidone therapy in combination with amoxicillin, bismuth subcitrate, and omeprazole for eradication of Helicobacter pylori.

Authors:  Salman R Hasan; Vahabzadeh Vahid; Pahlvanzadah M Reza; Salman R Roham
Journal:  Saudi J Gastroenterol       Date:  2010 Jan-Mar       Impact factor: 2.485

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.